Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    April 2022
  1. VANDE CASTEELE N
    Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    JAMA. 2022;327:1506.
    PubMed    


  2. JAVOR E, Hauser G, Skelin M
    Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    JAMA. 2022;327:1505-1506.
    PubMed    


  3. SYVERSEN SW, Jahnsen J, Haavardsholm EA
    Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.
    JAMA. 2022;327:1506-1507.
    PubMed    


    December 2021
  4. SYVERSEN SW, Jorgensen KK, Goll GL, Brun MK, et al
    Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    JAMA. 2021;326:2375-2384.
    PubMed     Abstract available


    October 2021
  5. ABBASI J
    Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases.
    JAMA. 2021;326:1365.
    PubMed    


    September 2021
  6. SERKLAND TT, Skrede S, Berg JA
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;326:1068-1069.
    PubMed    


  7. LE TILLY O, Paintaud G, Ternant D
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;326:1069.
    PubMed    


  8. PAPAMICHAIL K, Dubinsky MC, Cheifetz AS
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;326:1067-1068.
    PubMed    


  9. SYVERSEN SW, Bolstad N, Haavardsholm EA
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
    JAMA. 2021;326:1069-1070.
    PubMed    


    July 2021
  10. SLOMSKI A
    Filgotinib Induces and Maintains Ulcerative Colitis Remission.
    JAMA. 2021;326:299.
    PubMed    


    May 2021
  11. BAYOUMY AB, de Boer NKH, Mulder CJJ
    Management of Crohn Disease.
    JAMA. 2021;325:1793-1794.
    PubMed    


  12. CUSHING K, Higgins PDR
    Management of Crohn Disease-Reply.
    JAMA. 2021;325:1794-1795.
    PubMed    


  13. CURTIS JR, Ogdie A, George MD
    Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;325:1726-1728.
    PubMed    


  14. SYVERSEN SW, Goll GL, Jorgensen KK, Sandanger O, et al
    Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    JAMA. 2021;325:1744-1754.
    PubMed     Abstract available


    January 2021
  15. CUSHING K, Higgins PDR
    Management of Crohn Disease: A Review.
    JAMA. 2021;325:69-80.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: